| Spiriva |
All Financial Data in US $ (mln) |
| Word Search (Top 10 - by date) |
Boehringer Ingelheim Celebrates its 125-year Existence and Looks to the Future With Confidence Boehringer Ingelheim
(August 27, 2010)
|
Vectura Group plc - Preliminary Results Vectura
(June 07, 2010)
|
Pearl Therapeutics’ Data for Its Combination Bronchodilator Product, PT003, SUPPORT THE POTENTIAL FOR Improvement in the Treatment of Patients With COPD Pearl Therapeutics
(May 18, 2010)
|
Pearl Therapeutics’ Bronchodilator Combination Therapeutic for COPD to be Presented at the American Thoracic Society Annual Meeting Pearl Therapeutics
(May 05, 2010)
|
Pfizer Reports First-Quarter 2010 Results Pfizer
(May 04, 2010)
|
Boehringer Ingelheim Grows Faster Than the Pharmaceutical Market for the Tenth Time in Succession / Continued High Level of Investment in R&D / Market Launch of Five Innovative Medicines Planned Boehringer Ingelheim
(April 20, 2010)
|
Sandoz to Acquire Oriel Therapeutics, Gaining Rights to Portfolio of Respiratory Products Targeting Asthma and COPD Novartis
(April 19, 2010)
|
Pearl Therapeutics Announces Positive Results from Phase 1 Trial of PT003, a Bronchodilator Combination Therapeutic for Chronic Obstructive Pulmonary Disease, and Initiation of Phase 2b Trial Pearl Therapeutics
(March 29, 2010)
|
Pfizer Reports Fourth-Quarter and Full-Year 2009 Results Pfizer
(February 03, 2010)
|
Pearl Therapeutics Announces Positive Results from Phase 2a Trial of Glycopyrrolate Inhalation Aerosol in Chronic Obstructive Pulmonary Disease Pearl Therapeutics
(January 06, 2010)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
| Summary Product Name Information |
|
|
| Product Sales Summary 2007/08 |
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2007 |
2008
|
2008 |
| Spiriva2 |
|
|
|
2,457 |
3,042 |
|
+24% |
|
|
Note: Shaded Cells3 |
|
|
More Product Information for EvaluatePharma® subscribersSubscribers see:
- Sales (historic and forecast to 2016 where available) listed by the reporting company or companies, including royalty, license and JV revenue where applicable
- Details of all events impacting the product
- Detailed product information, including sales forecasts listed by the reporting company or companies, indications (approved and in trial)
|
Register to access more FREE content:
- 2009 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
|
|
|
|